Many Patients Don't Receive Indicated Targeted NSCLC Therapy

The rates of use of targeted therapy among patients with EGFR- and ALK-mutations also varied across the US, dropping below 20% in some states.
Medscape Medical News

source https://www.medscape.com/viewarticle/987655?src=rss